Antiplatelet drug

(redirected from Platelet aggregation inhibitor)

Antiplatelet drug

Drug that inhibits platelets from aggregating to form a plug. They are used to prevent clotting and alter the natural course of atherosclerosis.
References in periodicals archive ?
Only 28% of all patients in the trial, sponsored by Ortho Biotech Clinical Affairs, were on a platelet aggregation inhibitor such as aspirin.
1 Market Share (%) for the Leading Products in the Platelet Aggregation Inhibitor Market, 2008
is a platelet aggregation inhibitor mainly used during and after coronary artery procedures such as angioplasty to prevent platelets from sticking together and causing thrombus formation within the coronary arteries.
Plavix (clopidogrel), a platelet aggregation inhibitor, is BMS' largest selling product and continues to make substantial year-on-year sales growth.
In the long term, Eli Lilly owns a robust late-stage drug pipeline including Arxxant for diabetic retinopathy and Prasugrel, a platelet aggregation inhibitor in the same mechanistic class as Plavix (Bristol-Myers Squibb;BMY/Sanofi-Aventis;SNY) for cardiovascular disease.
There is a distinct medical need for a platelet aggregation inhibitor that is rapidly reversible and that could potentially reduce complications arising from surgeries such as coronary artery bypass graft and valve replacements," stated Christy L.
In addition, he co-headed the company's manufacturing project team for its platelet aggregation inhibitor INTEGRILIN(R), which is approved in major countries worldwide.
The patent awarded covers the basic composition of TP-9201, a platelet aggregation inhibitor, and related compositions for the treatment of thrombosis," said Dr.
Included in the portfolio is: an anti-thrombotic platelet aggregation inhibitor which has successfully completed Phase I Clinical Trials; a surface coating which reduces or eliminates the body's attempt to encapsulate or wall off an implant; potent anti-angiogenesis peptides which could play an important role in the control of cancerous tumors; and anti-fibrosis molecules which could create a totally new approach to the treatment of fibrotic diseases.
RGD peptide products under development include a cell adhesive coating designed to improve the performance of implantable devices and their acceptance by the body, and a platelet aggregation inhibitor designed to prevent unwanted blood clotting without causing bleeding at therapeutic doses, unlike certain therapies now existing or under development by others.
Telios' products under development include a cell adhesive coating designed to improve the performance of implantable devices and their acceptance by the body, and a platelet aggregation inhibitor designed to prevent unwanted blood clotting without causing bleeding at therapeutic doses, unlike certain therapies now existing or under development by others.
These findings may position TP-9201 as a novel platelet aggregation inhibitor and broaden the market opportunity by enabling treatment of indications in which bleeding caused by anti-thrombotics currently in use or under development puts patients at risk," said Donald W.

Full browser ?